Mimedx Group, Inc (NASDAQ:MDXG)

Thursday, July 26, 2012 | Web News
Second Quarter 2012 Results The Company recorded record revenue of $4.9 million for the second quarter of 2012, a 153% or $3....
Wednesday, July 18, 2012 | Web News
As of March 31, 2012, the Company had approximately $3,021,000 of cash and cash equivalents. The Company reported total current assets of approximately $...
See All Research...

This stock has been identified as a shell company.

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion® process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant for homologous use. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 70,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthopedics, Spine, Wound Care and Dental sectors of healthcare.

Reverse Merger filing

Web site: http://www.mimedx.com

Last updated June 15, 2012


Market Data powered by QuoteMedia. Terms of Use